Poor Man -,
I also tend to agree because this will be made out to be just more interim news no matter how much it gets talked about. The first thing new folks see is stock price and OTC. Big red flags for main line investors. The market would have been excited if the journal came out a year ago before SNO. Now, not so much because of the time elapsed and questions as to why such an important breakthrough has not received more main line attention and a quicker pathway forward. They won’t consider why the opposition has been so staunch or that Linda was trying to protect the treatment from being shelved or other. They just want a simple reason to invest in something that others will invest in after them thus driving up the price. That simple answer is manufacturing approval followed by marketing authorization which to me seems to be why the journal article appears to have been linked to manufacturing approval so that the company can then say to the market convincingly that they have applied for marketing authorization and that their application has been accepted or better yet, approved. Anything else is a set up for disappointment so no ASM until they have a good reason to have one. I think they hope to have that good reason “soon” as defined previously by me in response to HappyLibrarian. Best wishes.
Market Data 
Markets 
AI
